(Reuters) – Drugmaker Bristol Myers Squibb said on Thursday the U.S. Food and Drug Administration had approved its oral drug mavacamten for the treatment of a heart condition.
(Reporting by Bhanvi Satija and Amruta Khandekar in Bengaluru Jaiveer Singh Shekhawat in Bengaluru; Editing by Subhranshu Sahu)
